| First Author | Xie Q | Year | 2007 |
| Journal | Mol Immunol | Volume | 44 |
| Issue | 14 | Pages | 3453-61 |
| PubMed ID | 17477969 | Mgi Jnum | J:123571 |
| Mgi Id | MGI:3718839 | Doi | 10.1016/j.molimm.2007.03.018 |
| Citation | Xie Q, et al. (2007) Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 44(14):3453-61 |
| abstractText | IRAK-M is a negative regulator of innate immunity signaling processes. Although attenuation of innate immunity may help to prevent excessive inflammation, it may also lead to compromised immune surveillance of tumor cells and contribute to tumor formation and growth. Here, we demonstrate that IRAK-M(-/-) mice are resistant to tumor growth upon inoculation with transplantable tumor cells. Immune cells from IRAK-M(-/-) mice are responsible for the anti-tumor effect, since adoptive transfer of splenocytes from IRAK-M(-/-) mice to wild type mice can transfer the tumor-resistant phenotype. Upon tumor cell challenge, there are elevated populations of CD4(+) and CD8(+) T cells and a decreased population of CD4(+) CD25(+)Foxp3(+) regulatory T cells in IRAK-M(-/-) splenocytes. Furthermore, we observe that IRAK-M deficiency leads to elevated proliferation and activation of T cells and B cells. Enhanced NFkappaB activation directly caused by IRAK-M deficiency may explain elevated activation of T and B cells. In addition, macrophages from IRAK-M(-/-) mice exhibit enhanced phagocytic function toward acetylated LDL and apoptotic thymocytes. Collectively, we demonstrate that IRAK-M is directly involved in the regulation of both innate and adaptive immune signaling processes, and deletion of IRAK-M enhances host anti-tumor immune response. |
